{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:34Z","timestamp":1790352514791,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Talimogene laherparepvec (T-VEC) is an oncolytic virus, approved for the treatment of stage IIIb-IVM1a melanoma with injectable disease (cutaneous, subcutaneous or lymphatic). It is a modified herpes simplex virus type 1 that induces tumor-specific T-cell responses via reduction of virally mediated suppression of antigen presentation, stimulation of viral pathogenicity and enhancement of tumor-selective replication. Response rates up to 82.6% have been reported for stage III disease. Acral lentiginous melanoma (ALM) is a rare subtype of melanoma with a poor prognosis. Here, we present a case of an elderly and frail patient with primary ALM who refused surgical treatment and consented to receive T-VEC as first-line drug therapy. After 10 courses of treatment, a histopathologically confirmed complete response was achieved. To our knowledge, this is the first case ever reported in which a primary ALM is (successfully) treated with T-VEC.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000673","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T07:31:09Z","timestamp":1591687869000},"page":"548-551","source":"Crossref","is-referenced-by-count":8,"title":["Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma"],"prefix":"10.1097","volume":"30","author":[{"given":"Viola","family":"Franke","sequence":"first","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe M.G.","family":"Smeets","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline E.","family":"van der Wal","sequence":"additional","affiliation":[{"name":"Pathology, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(18)31071-7","article-title":"Acral lentiginous melanoma.","volume":"391","author":"Liu","year":"2018","journal-title":"Lancet"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2007.12.3604","article-title":"Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.","volume":"26","author":"Zell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-319-22539-5_14","article-title":"Acral lentiginous melanoma.","volume":"167","author":"Goydos","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20230902","first-page":"11","article-title":"Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.","volume":"3","author":"Hughes","year":"2014","journal-title":"Oncolytic Virother"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.32172","article-title":"High response rates for T-VEC in early metastatic melanoma (stage IIIB\/C-IVM1a).","volume":"145","author":"Franke","year":"2019","journal-title":"Int J Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"MMT19","DOI":"10.2217\/mmt-2019-0012","article-title":"Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).","volume":"6","author":"Perez","year":"2019","journal-title":"Melanoma Manag"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14712598.2020.1689951","article-title":"An evaluation of talimogene laherparepvec for the treatment of melanoma.","volume":"20","author":"Broman","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience.","volume":"228","author":"Louie","year":"2019","journal-title":"J Am Coll Surg"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12325-018-0850-6","article-title":"Real-world use of talimogene laherparepvec in German patients with stage IIIB to IVM1a melanoma: a retrospective chart review and physician survey.","volume":"36","author":"Mohr","year":"2019","journal-title":"Adv Ther"},{"key":"R14-20230902","first-page":"S0190-9622(20)30123-7","article-title":"Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma.","volume":"pii","author":"Haitz","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjsurg.2012.05.013","article-title":"Unique prognostic factors in acral lentiginous melanoma.","volume":"204","author":"Egger","year":"2012","journal-title":"Am J Surg"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/BF02305539","article-title":"Plantar flap reconstruction for acral lentiginous melanoma.","volume":"4","author":"Evans","year":"1997","journal-title":"Ann Surg Oncol"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ced.12469","article-title":"Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells.","volume":"40","author":"Savarese","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"bcr2014203826","DOI":"10.1136\/bcr-2014-203826","article-title":"Use of imiquimod for residual acral melanoma.","volume":"2014","author":"Sue","year":"2014","journal-title":"BMJ Case Rep"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/120347541201600405","article-title":"Topical 5% imiquimod in the treatment of lentigo maligna.","volume":"16","author":"Wong","year":"2012","journal-title":"J Cutan Med Surg"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:06:21Z","timestamp":1693627581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000673","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}